학술논문
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
Document Type
Review Article
Author
Source
In Seminars in Oncology 2001 29 Supplement 2:4-9
Subject
Language
ISSN
0093-7754